FDA Updates Atazanavir Sulfate Capsule Labeling
“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes.
“Section 5 Warnings and Precautions was revised to include cholelithiasis ...
“In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added.
“In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Atazanavir (Reyataz) patient drug summary
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Carbamazepine | Department of Health | Gallstones | Health | HIV AIDS | Infectious Diseases | Lamictal | Nephritis | Phenobarbital | Phenytoin | Reyataz | Warnings | Websites